Arbutus Biopharma Corp (ABUS)
3.955
+0.10
(+2.46%)
USD |
NASDAQ |
Nov 05, 16:00
3.955
0.00 (0.00%)
After-Hours: 18:33
Arbutus Biopharma Enterprise Value: 586.71M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 586.71M |
| November 01, 2024 | 605.59M |
| October 31, 2024 | 583.88M |
| October 30, 2024 | 601.82M |
| October 29, 2024 | 620.69M |
| October 28, 2024 | 622.58M |
| October 25, 2024 | 607.48M |
| October 24, 2024 | 622.58M |
| October 23, 2024 | 624.47M |
| October 22, 2024 | 618.81M |
| October 21, 2024 | 626.36M |
| October 18, 2024 | 641.46M |
| October 17, 2024 | 635.80M |
| October 16, 2024 | 650.90M |
| October 15, 2024 | 633.91M |
| October 14, 2024 | 586.71M |
| October 11, 2024 | 590.49M |
| October 10, 2024 | 573.50M |
| October 09, 2024 | 567.83M |
| October 08, 2024 | 569.72M |
| October 07, 2024 | 562.17M |
| October 04, 2024 | 582.94M |
| October 03, 2024 | 584.82M |
| October 02, 2024 | 594.26M |
| October 01, 2024 | 581.05M |
| Date | Value |
|---|---|
| September 30, 2024 | 584.82M |
| September 27, 2024 | 581.05M |
| September 26, 2024 | 605.59M |
| September 25, 2024 | 596.15M |
| September 24, 2024 | 616.92M |
| September 23, 2024 | 620.69M |
| September 20, 2024 | 616.92M |
| September 19, 2024 | 639.57M |
| September 18, 2024 | 637.68M |
| September 17, 2024 | 628.24M |
| September 16, 2024 | 662.23M |
| September 13, 2024 | 701.87M |
| September 12, 2024 | 671.66M |
| September 11, 2024 | 718.86M |
| September 10, 2024 | 718.86M |
| September 09, 2024 | 705.65M |
| September 06, 2024 | 716.97M |
| September 05, 2024 | 709.42M |
| September 04, 2024 | 630.13M |
| September 03, 2024 | 611.25M |
| August 30, 2024 | 588.60M |
| August 29, 2024 | 581.05M |
| August 28, 2024 | 584.82M |
| August 27, 2024 | 588.60M |
| August 26, 2024 | 588.60M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
119.19M
Minimum
Apr 03 2020
718.86M
Maximum
Sep 10 2024
315.14M
Average
290.48M
Median
Nov 04 2020
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 12.24B |
| GlycoMimetics Inc | 4.052M |
| FibroGen Inc | 6.090M |
| Cidara Therapeutics Inc | -72.66M |
| Cue Biopharma Inc | 65.63M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.80M |
| Revenue (Quarterly) | 1.726M |
| Total Expenses (Quarterly) | 23.10M |
| EPS Diluted (Quarterly) | -0.11 |
| Profit Margin (Quarterly) | -1.15K% |
| Earnings Yield | -11.38% |
| Normalized Earnings Yield | -11.26 |